Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2023-03-15 Capital/Financing Update
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release dated March 14, 2023, announcing the closing of a private placement financing by LSL Pharma Group Inc. It details the amount raised, the number of units issued, the price per unit, and the terms of the warrants issued. It also mentions the use of proceeds and regulatory approvals pending. There is no detailed financial report, no earnings data, no management discussion, no audit information, or other report content. The document is clearly an update on a financing activity (private placement) and not a full financial report or other filing type. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short and focused solely on the financing announcement, supporting this classification with high confidence.
2023-03-15 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2023-03-03 English
Material change report - English.pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and references the British Columbia Securities Commission (BCSC). This form is a regulatory filing used to report exempt distributions of securities, typically related to private placements or exempt offerings. The content includes issuer information, underwriter information, and certification details, which are typical for regulatory compliance filings rather than financial reports or announcements. There is no indication of financial statements, earnings data, management discussion, or meeting materials. The document is a regulatory compliance report rather than an annual report, earnings release, or capital update. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-03-03 English
Material document(s).pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Warrant Indenture Providing for the Issue of Warrants' and contains detailed legal and contractual provisions related to the issuance, exercise, and rights associated with warrants. It includes articles on interpretation, issuance, exercise, adjustments, rights, enforcement, meetings, supplemental indentures, and the warrant agent's duties. This is a legal contract document governing the terms of warrants issued by the company, not a financial report, earnings release, or announcement. It is not a regulatory filing or announcement but a formal indenture agreement. Therefore, the most appropriate classification is 'Capital/Financing Update (CAP)' as it relates to financing instruments and capital structure changes through warrants.
2023-03-03 English
Material document(s).pdf
Regulatory Filings Classification · 95% confidence The document is a detailed legal agreement titled 'Formulaire 5D Convention d'Entiercement Titres Excédentaires' involving Groupe LSL Pharma Inc. and a trust company acting as escrow agent. It outlines terms for escrow of excess securities, conditions for release, restrictions on transfer, and other operational details related to securities held in escrow. The content is focused on securities escrow arrangements and compliance with stock exchange policies, not on financial results, management changes, or shareholder votes. It is a regulatory or compliance-related filing concerning securities escrow agreements rather than a financial report, announcement, or management communication. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or compliance documents that do not fit other specific categories.
2023-03-03 English
Material change report - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the results of an annual and extraordinary shareholders meeting, including approval of a reverse takeover transaction, private placement, changes in board composition, auditor appointment, share consolidation, and name change. It also announces the closing of the transaction and the listing of shares on the TSX Venture Exchange. The document includes detailed descriptions of the transaction terms, share issuances, and corporate actions approved by shareholders. It is not a full annual report or financial statement but rather a comprehensive announcement of corporate governance changes, financing activities, and shareholder meeting results. The primary focus is on the transaction closing and private placement, which are capital raising activities, along with board changes and shareholder approvals. Given the detailed nature of the transaction and financing information, the document best fits the category of Capital/Financing Update (CAP). It is not merely a brief press release or a proxy solicitation, but a substantive update on financing and corporate restructuring.
2023-03-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.